Metacrine, Inc. (NASDAQ:MTCR) Sees Significant Decrease in Short Interest
Metacrine, Inc. (NASDAQ:MTCR) Sees Significant Decrease in Short Interest
Metacrine, Inc. (NASDAQ:MTCR – Get Rating) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 87,400 shares, a decrease of 61.8% from the December 31st total of 228,600 shares. Based on an average daily volume of 328,600 shares, the short-interest ratio is currently 0.3 days.
梅特克林公司（NASDAQ：MTCR-獲取評級）是一月份短期利益顯著減少的收件人。截至 1 月 15 日，總共有 87,400 股股份的短期利息，較十二月三十一日共 228,600 股股份下降了 61.8%。根據每日平均成交量為 328,600 股，短息比率目前為 0.3 天。
Insider Buying and Selling at Metacrine
在 Metacrine 進行內幕購買和銷售
In other news, major shareholder Braden Michael Leonard bought 123,954 shares of the stock in a transaction on Monday, November 7th. The stock was purchased at an average price of $0.42 per share, with a total value of $52,060.68. Following the completion of the purchase, the insider now owns 5,848,649 shares of the company's stock, valued at $2,456,432.58. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders bought 430,275 shares of company stock valued at $174,191. Corporate insiders own 11.40% of the company's stock.
在其他消息中，主要股東布拉登邁克爾·倫納德在 11 月 7 日（星期一）的一項交易中購買了 123,954 股。該股票以每股 0.42 美元的平均價格購入，總價值為 52,060.68 美元。購買完成後，內幕人士現在擁有該公司股票的 5,848,649 股股份，價值為 2,456,432.58 美元。購買在與 SEC 提交的文件中披露，該文件可通過以下方式訪問 此超連結。在過去 90 天內，內部人士購買了價值 174,191 美元的公司股票 430,275 股。企業內部人士擁有公司股票的 11.40%。
Institutional Inflows and Outflows
機構流入和流出
Several large investors have recently added to or reduced their stakes in the business. State Street Corp lifted its stake in Metacrine by 482.8% in the second quarter. State Street Corp now owns 72,186 shares of the company's stock valued at $36,000 after acquiring an additional 59,800 shares during the last quarter. Citadel Advisors LLC lifted its stake in Metacrine by 112.5% in the third quarter. Citadel Advisors LLC now owns 136,606 shares of the company's stock valued at $66,000 after acquiring an additional 72,306 shares during the last quarter. Jane Street Group LLC acquired a new stake in Metacrine in the third quarter valued at $84,000. Bank of New York Mellon Corp acquired a new stake in Metacrine in the first quarter valued at $126,000. Finally, Bank of America Corp DE lifted its stake in Metacrine by 10.5% in the first quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after acquiring an additional 24,964 shares during the last quarter. Institutional investors and hedge funds own 34.28% of the company's stock.
一些大型投資者最近增加或減少了他們在業務中的賭注。州街公司在第二季度將其對梅特克林的股份提升了 482.8％。州街公司現在擁有該公司的 72,186 股股份，價值 36,000 美元，在上個季度額外收購 59,800 股後。城堡顧問有限責任公司在第三季度將其在梅塔克林的股份提升了 112.5％。城堡顧問有限責任公司現在擁有該公司股票的 136,606 股，價值為 66,000 美元，在上一季度獲得了額外的 72,306 股之後。簡街集團有限責任公司在第三季度收購了梅特克林的新股份，價值為 84,000 美元。紐約梅隆銀行在第一季度收購了一股價值 126,000 美元的新股份。最後，美國銀行公司 DE 在第一季度將其對梅塔克林的股份提高了 10.5％。美國銀行股份有限公司在上一季度額外收購了 24,964 股後，現在擁有該公司 263,340 股股票，價值為 161,000 美元。機構投資者和對沖基金擁有該公司股票的 34.28%。
Metacrine Price Performance
米塔克林價格表現
Metacrine (NASDAQ:MTCR – Get Rating) last announced its earnings results on Monday, November 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities research analysts anticipate that Metacrine will post -0.62 EPS for the current year.
梅塔克林（NASDAQ：MTCR-獲取評分）上次公佈了 11 月 14 日（星期一）的盈利業績。該公司報告了本季每股盈利（0.13 美元），缺少了（0.11 美元）的共識估計（0.02 美元）。平均而言，股票研究分析師預計，本年度 Metacrine 的每股收益將為 -0.62。
Analyst Ratings Changes
分析師等級變更
Separately, HC Wainwright reissued a "neutral" rating on shares of Metacrine in a research report on Wednesday, November 16th.
另外，HC 溫賴特在 11 月 16 日（星期三）的一份研究報告中重新發布了對米特克林股份的「中性」評級。
Metacrine Company Profile
梅特克林公司簡介
(Get Rating)
(取得評分)
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對胃腸疾病患者的療法。它正在開發 MET642，該試驗已完成治療潰瘍性結腸炎的 I 期臨床試驗。梅塔克林公司成立於 2014 年，總部位於加利福尼亞州聖地牙哥。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
- 獲取有關二甲基林（MTCR）的研究報告的免費副本
- 電子商務的未來：分析與新數據
- 雪佛龍以 750 億美元的股份回購令股東感到滿意
- 列維·施特勞斯是一個非常適合收入投資者
- 3 個有大上升空間的小型大寫字母
- 馬倫汽車：好消息，壞的和醜陋的前景
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.
接收梅塔克林日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Metacrine 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。